Richard Görlick

29.8k total citations · 7 hit papers
363 papers, 18.2k citations indexed

About

Richard Görlick is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Richard Görlick has authored 363 papers receiving a total of 18.2k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Pulmonary and Respiratory Medicine, 146 papers in Molecular Biology and 142 papers in Oncology. Recurrent topics in Richard Görlick's work include Sarcoma Diagnosis and Treatment (145 papers), Neuroblastoma Research and Treatments (65 papers) and Cancer Genomics and Diagnostics (37 papers). Richard Görlick is often cited by papers focused on Sarcoma Diagnosis and Treatment (145 papers), Neuroblastoma Research and Treatments (65 papers) and Cancer Genomics and Diagnostics (37 papers). Richard Görlick collaborates with scholars based in United States, Australia and Canada. Richard Görlick's co-authors include Jonathan Gill, Paul A. Meyers, David S. Geller, John H. Healey, E. Anders Kolb, Stefan Bielack, Alexander J. Chou, Andrew G. Huvos, Michael S. Isakoff and Paul S. Meltzer and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Richard Görlick

357 papers receiving 17.9k citations

Hit Papers

Osteosarcoma: Current Treatment and a Colla... 2004 2026 2011 2018 2015 2004 2021 2017 2004 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
    2015 1.2k citations Michael S. Isakoff, Richard Görlick et al. Journal of Clinical Oncology profile →
  2. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
    2004 572 citations Chand Khanna, Richard Görlick et al. profile →
  3. Advancing therapy for osteosarcoma
    2021 559 citations Jonathan Gill, Richard Görlick profile →
  4. Current and future therapeutic approaches for osteosarcoma
    2017 539 citations Douglas J. Harrison, David S. Geller et al. profile →
  5. Biology and Therapeutic Advances for Pediatric Osteosarcoma
    2004 535 citations Neyssa Marina, Lisa A. Teot et al. profile →
  6. Osteosarcoma: a review of diagnosis, management, and treatment strategies.
    2010 394 citations David S. Geller, Richard Görlick profile →
  7. Osteosarcoma
    2022 337 citations Jonathan Gill, Katherine A. Janeway et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Görlick United States 71 8.8k 6.9k 5.7k 4.1k 2.1k 363 18.2k
Lee J. Helman United States 67 7.0k 0.8× 5.0k 0.7× 4.0k 0.7× 2.4k 0.6× 998 0.5× 208 14.3k
Timothy J. Triche United States 70 7.4k 0.8× 7.8k 1.1× 3.7k 0.7× 2.8k 0.7× 2.1k 1.0× 268 17.0k
Silvana Pilotti Italy 68 5.1k 0.6× 5.3k 0.8× 6.6k 1.1× 2.7k 0.6× 2.3k 1.1× 294 16.2k
Yoshinao Oda Japan 64 6.3k 0.7× 7.7k 1.1× 8.7k 1.5× 2.8k 0.7× 2.3k 1.1× 948 20.4k
Paul A. Meyers United States 66 4.2k 0.5× 9.0k 1.3× 4.2k 0.7× 1.8k 0.4× 3.3k 1.6× 262 15.7k
Noel Weidner United States 49 8.8k 1.0× 4.3k 0.6× 5.4k 0.9× 5.5k 1.3× 1.2k 0.6× 183 17.9k
Marco A. Pierotti Italy 85 13.3k 1.5× 5.5k 0.8× 10.7k 1.9× 5.5k 1.3× 1.6k 0.8× 457 27.2k
Jessica Zucman‐Rossi France 82 13.9k 1.6× 7.7k 1.1× 7.2k 1.3× 7.8k 1.9× 1.3k 0.6× 322 31.8k
Stefan Bielack Germany 52 4.1k 0.5× 8.6k 1.2× 3.8k 0.7× 2.6k 0.6× 3.8k 1.9× 215 14.0k
Jonathan Said United States 73 8.5k 1.0× 5.2k 0.7× 8.2k 1.4× 3.5k 0.8× 549 0.3× 370 20.5k

Countries citing papers authored by Richard Görlick

Since Specialization
Citations

This map shows the geographic impact of Richard Görlick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Görlick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Görlick more than expected).

Fields of papers citing papers by Richard Görlick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Görlick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Görlick. The network helps show where Richard Görlick may publish in the future.

Co-authorship network of co-authors of Richard Görlick

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Görlick. A scholar is included among the top collaborators of Richard Görlick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Görlick. Richard Görlick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shulman, David S., Kelly Klega, Allen Buxton, et al.. (2024). Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).. Journal of Clinical Oncology. 42(16_suppl). 10018–10018. 1 indexed citations
2.
Yang, Qing, Jiemiao Hu, Zhiliang Jia, et al.. (2022). Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. Clinical Cancer Research. 28(17). 3862–3873. 13 indexed citations
3.
Hingorani, Pooja, Wendong Zhang, Zhaohui Xu, et al.. (2022). Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. Molecular Cancer Therapeutics. 21(8). 1318–1325. 12 indexed citations
4.
Hingorani, Pooja, Mark Krailo, Allen Buxton, et al.. (2022). Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. European Journal of Cancer. 172. 264–275. 23 indexed citations
5.
Hingorani, Pooja, Michael Roth, Wendong Zhang, et al.. (2020). ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Molecular Cancer Therapeutics. 20(3). 535–540. 23 indexed citations
6.
Zhang, Yidan, et al.. (2019). Assessment of patient experiences following total sacrectomy for primary malignant sacral tumors: A qualitative study. Journal of Surgical Oncology. 120(8). 1497–1504. 3 indexed citations
7.
Murphy, Brendan, John M. Maris, E. Anders Kolb, et al.. (2016). Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Research. 76(19). 5798–5809. 40 indexed citations
8.
Vo, Kieuhoa T., C. Lorrie Epling, Elizabeth Sinclair, et al.. (2016). Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(14). 3643–3650. 17 indexed citations
9.
Smith, Malcolm A., C. Patrick Reynolds, Min H. Kang, et al.. (2014). Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research. 21(4). 819–832. 90 indexed citations
10.
Geller, David S., Wendong Zhang, Jonathan Gill, et al.. (2014). Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. Clinical Cancer Research. 21(13). 3003–3012. 12 indexed citations
11.
Meyers, Paul A., Holcombe E. Grier, Mark L. Bernstein, et al.. (2012). Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(20). 2545–2551. 184 indexed citations
12.
Houghton, Peter J., Christopher L. Morton, Richard Görlick, et al.. (2010). Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics. 9(1). 101–112. 79 indexed citations
13.
Humeniuk, Rita, Lata G. Menon, Prasun Mishra, et al.. (2009). Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Molecular Cancer Therapeutics. 8(5). 1037–1044. 43 indexed citations
14.
Görlick, Richard, E. Anders Kolb, Peter J. Houghton, et al.. (2009). Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53(4). 594–598. 26 indexed citations
15.
Neale, Geoffrey, Xiaoping Su, Christopher L. Morton, et al.. (2008). Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research. 14(14). 4572–4583. 95 indexed citations
16.
Lu, Xinyan, Yaojuan Lu, Jason Kang, et al.. (2008). Cell Cycle Regulator Gene CDC5L , a Potential Target for 6p12-p21 Amplicon in Osteosarcoma. Molecular Cancer Research. 6(6). 937–946. 65 indexed citations
17.
18.
Zelcer, Shayna, Michael Kellick, Leonard H. Wexler, Richard Görlick, & Paul A. Meyers. (2008). The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatric Blood & Cancer. 50(6). 1176–1180. 39 indexed citations
19.
Whiteford, Craig C., Sven Bilke, Braden T. Greer, et al.. (2007). Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis. Cancer Research. 67(1). 32–40. 91 indexed citations
20.
Antunes, Nuno Lobo, et al.. (2000). Numb Chin Syndrome in Ewing Sarcoma. ˜The œAmerican journal of pediatric hematology/oncology. 22(6). 521–523. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lee J. Helman Breakdown of academic impact, for papers by Timothy J. Triche Breakdown of academic impact, for papers by Silvana Pilotti Breakdown of academic impact, for papers by Yoshinao Oda Breakdown of academic impact, for papers by Paul A. Meyers Breakdown of academic impact, for papers by Noel Weidner Breakdown of academic impact, for papers by Marco A. Pierotti Breakdown of academic impact, for papers by Jessica Zucman‐Rossi Breakdown of academic impact, for papers by Stefan Bielack Breakdown of academic impact, for papers by Jonathan Said
Rankless by CCL
2026